Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a master protocol study titled ‘A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain.’ The study aims to compare various pain interventions to establish a comprehensive framework for disease-specific addenda and intervention-specific appendices, focusing on chronic pain conditions such as osteoarthritis, chronic low back pain, and diabetic peripheral neuropathic pain.
The study tests several experimental drugs, including LY3016859, LY3556050, LY3526318, and LY3857210, each administered either intravenously or orally. These interventions are designed to alleviate chronic pain and are compared against placebos to assess their effectiveness.
This randomized, double-blind, parallel-assignment study primarily aims to screen the effectiveness of these interventions in treating chronic pain. Participants and investigators are blinded to the interventions to ensure unbiased results.
The study began on January 30, 2020, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025, indicating ongoing progress in the study.
The update on this study could influence Eli Lilly’s stock performance positively, as successful outcomes may enhance the company’s position in the chronic pain treatment market. This could also affect investor sentiment, especially in comparison to competitors in the pharmaceutical industry focusing on pain management.
The study is currently recruiting, with further details available on the ClinicalTrials portal.